HOTTIP and nonpapillary renal cell carcinoma: More importantly, we found that patients with high HOTTIP expression were less sensitive to clinical therapeutic drugs, including gemcitabine, pazopanib, sunitinib, and XL-184, than patients with low HOTTIP expression, indicating that high HOTTIP expression may lead to drug resistance in ccRCC patients.